timothy sykes logo
RXRX Stock Plummet: Here’s What’s Happening Thumbnail
ADD US ONG Google News

RXRX Stock Plummet: Here’s What’s Happening

TIM SYKES•UPDATED DEC. 29, 2025, 2:33 PM ET
Reviewed by Jack Kellogg Fact-checked by Ellis Hobbs

Recursion Pharmaceuticals Inc.’s stock, trading down by -3.18%, is pressured by investor concerns over strategic pivots.

Candlestick Chart

Live Update At 14:32:32 EST: On Monday, December 29, 2025 Recursion Pharmaceuticals Inc. stock [NASDAQ: RXRX] is trending down by -3.18%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Overview: A Peek Into The Numbers

As millionaire penny stock trader and teacher Tim Sykes, says, “Preparation plus patience leads to big profits.” This principle holds especially true in the world of trading. Success in trading doesn’t happen overnight, and those who take the time to prepare thoroughly and remain patient are more likely to see significant returns. This approach requires constant learning and discipline, but the potential rewards make it worthwhile. As traders, understanding the market, having a solid strategy, and staying patient can truly make the difference.

Recursion Pharmaceuticals Inc. has recently unveiled some financials that deserve a closer look. The company’s revenue is reported at a little over $58M, while the balance sheets depict total assets around $1.39 billion. For a company dwelling on its research foundations, such tangible progress might seem commendable. However, the deeper numbers paint a slightly concerning picture. Most notably, a daunting ebit margin at negative 1,640.3% flagging visibly high operating costs.

The substantial gross margin, dipping below 60%, hints at underlying inefficiencies. Combine that with a troubling profitability outline – negative 921.5% pretax profit margins – and the scenario leans towards cautious territory. Although the company has succeeded in garnering substantial equity through stock issuance, cash flows echo a different tune. The net common stock issuance fetched around $254M, but the negative change in overall cash reflects urgency in capital management.

Investors eyeing RXRX are particularly wary due to its high price-to-sales ratio at 50.57, indicating a potential overvaluation. Despite maintaining a favorable current ratio, reflecting good short-term liquidity, the firm’s ongoing returns are awash with caution as reflected through the ROAs and ROEs in negative terrains.

Impact of Recent News on Stock Price

Delving into the core events, Director Blake Borgeson’s sell-off of 220,000 shares stands out prominently. Generally, such insider sales can be viewed as a red flag, echoing potential liquidity needs or shifting confidence within the firm’s directional strategy. This naturally exerts selling pressure on the company’s stock, evident from a dip in recent prices.

More Breaking News

On a broader term, RXRX’s hold on its industry segment shows potential, yet current stock behaviors suggest a need for stratified progression. Without strong operational indicators or innovative leaps on the immediate horizon, the market may shoulder this stock with more skepticism. Any potential rebounds are likely contingent on ameliorating the negative sentiment stemming from their last earnings report and fundamental valuations.

Unveiling the Challenges: Can RXRX Bounce Back?

Understanding this stock’s trajectory necessitates a more thorough comprehension of its challenges. Recursion’s narratives revolve around its positioning in a tech-as-a-service ecosystem, yet the core financials starkly oppose long-term prospects. From high operational costs eating into profits to the hefty weight of overemphasized sustainability metrics, all point towards more calculated deliberations for investors.

The immeasurable cash burn, highlighted through various investment measures, highlights an immediate need for the company to pivot its approach. An urgency in revenue stream diversification and operational de-risking could potentialize progressive remedial action. However, carrying forth such a transition amidst ongoing market instability requires adroit cost management and rekindled investor trust.

On an empirical front, RXRX’s intra-day data points to erratic fluctuations, indicating both retail and institutional uncertainties. While the stock price meandered through highs and lows within narrow bands, a closer inspection of micro-movements reveals persistent resistance levels hovering near the $4 mark, yet unable to anchor growth momentum or establish new highs.

Conclusion

For potential traders, RXRX poses a conundrum fueled by both anticipation and skepticism. The ripple effect from insider action juxtaposes the backdrop of daunting financial metrics, accentuating the volatility of this equity. Whether its postures will turn praiseworthy hinges on how adeptly Recursion steers itself out of troubled waters, aligns priorities, and pragmatically reallocates resources to reinforce scalability.

The narrative unfolds into a dynamic conjecture of potential realized versus rhetoric presumed. Recursion’s performance, given the scrutiny, illustrates an opportune challenge – reluctant yet essential for strategic pivoting. As millionaire penny stock trader and teacher Tim Sykes says, “The goal is not to win every trade but to protect your capital and keep moving forward.” This serves as a reminder that the road to recovery might be long and demanding, but with calculated foresight, trader conviction intertwined with emergent innovations, RXRX may yet reposition itself creditably within the pharmaceuticals arena. Time, and agility, will be the ultimate arbiters.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading RXRX

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”